Eli Lilly and Novo Nordisk face new competition in slimming drugs market

The duopoly of US pharmaceuticals firm Eli Lilly and Danish Novo Nordisk in the slimming drugs market is threatened. 

Two firms, Viking Therapeutics and Roche, announced the development of three products and Viking's shot up 39% in one day. 

Goldman Sachs estimates the market for such drugs will grow from €14 billion to €130 billion by 2030.